Literature DB >> 2653080

Neurotoxicity due to central nervous system therapy for childhood leukemia.

J J Ochs1.   

Abstract

Therapy for occult or overt meningeal leukemia produces subclinical or clinical neurotoxicity in a variable proportion of children with acute lymphoblastic leukemia (ALL). The type, frequency, and permanence of these central nervous system (CNS) changes depend primarily on the therapy itself, although the contribution of additional factors, such as young age, may be substantial. Neurotoxicity in patients who have received 2,400 cGy cranial irradiation plus 5 concurrent doses of intrathecal methotrexate as CNS prophylaxis has been characterized more fully than the CNS changes accompanying other forms of therapy. Cross-sectional studies using cranial computed tomography scans to evaluate structural changes in the brain have shown ventricular dilatation in 15%, white matter hypodensity in 3.5%, and calcifications in 8%. The principal neuroendocrine effect is decreased growth velocity during therapy and adolescence, with significant decreases in final height in approximately one-third of children. Secondary cerebral gliomas with a poor prognosis are being reported with increasing regularity, but the true risk of this complication is still unknown. Use of parenteral methotrexate as the sole method of CNS prophylaxis is associated with transient focal white matter hypodensity. Neuroendocrine and neuropsychologic sequelae associated with this therapy are minimal; however, much of the available information is based on patients treated with regimens that had unacceptably high CNS relapse rates or whose length of follow-up was brief. With more aggressive, and hence more effective, prophylaxis with intrathecal methotrexate, spinal cord myelopathy may become a significant new area of neurotoxicity. Clinically significant CNS toxicity develops in the majority of patients who receive treatment for meningeal relapse. The leukemia itself is a prime contributing factor to this neurotoxicity. In patients who are subsequently cured of leukemia, acute neurotoxicity consists mainly of seizures; the most significant sequelae appearing after the cessation of therapy consists of significant drops in full scale IQ.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653080     DOI: 10.1097/00043426-198921000-00019

Source DB:  PubMed          Journal:  Am J Pediatr Hematol Oncol        ISSN: 0192-8562


  13 in total

Review 1.  Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis.

Authors:  Stacey L Berg; Marc C Chamberlain
Journal:  Curr Oncol Rep       Date:  2003-01       Impact factor: 5.075

Review 2.  CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsychological, and behavioral effects?

Authors:  J A Stehbens; T A Kaleita; R B Noll; W E MacLean; R T O'Brien; M J Waskerwitz; G D Hammond
Journal:  Neuropsychol Rev       Date:  1991-06       Impact factor: 7.444

3.  Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia.

Authors:  Wilburn E Reddick; Zuyao Y Shan; John O Glass; Susan Helton; Xiaoping Xiong; Shengjie Wu; Melanie J Bonner; Scott C Howard; Robbin Christensen; Raja B Khan; Ching-Hon Pui; Raymond K Mulhern
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

4.  Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.

Authors:  Wanda L Salzer; Michael J Burke; Meenakshi Devidas; Yunfeng Dai; Kristina K Hardy; John A Kairalla; Lia Gore; Joanne M Hilden; Eric Larsen; Karen R Rabin; Patrick A Zweidler-McKay; Michael J Borowitz; Brent Wood; Nyla A Heerema; Andrew J Carroll; Naomi Winick; William L Carroll; Elizabeth A Raetz; Mignon L Loh; Stephen P Hunger
Journal:  J Clin Oncol       Date:  2020-06-04       Impact factor: 44.544

5.  Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Authors:  Yousif Matloub; Susan Lindemulder; Paul S Gaynon; Harland Sather; Mei La; Emmett Broxson; Rochelle Yanofsky; Raymond Hutchinson; Nyla A Heerema; James Nachman; Marilyn Blake; Linda M Wells; April D Sorrell; Margaret Masterson; John F Kelleher; Linda C Stork
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

6.  Vincristine induced neurotoxicity in cancer patients.

Authors:  Sunil Gomber; Pooja Dewan; Devender Chhonker
Journal:  Indian J Pediatr       Date:  2010-01       Impact factor: 1.967

7.  Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: long-term follow up with cerebral computed tomography scans and endocrinological studies.

Authors:  H Hasle; J Helgestad; J K Christensen; B B Jacobsen; J Kamper
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

8.  Intellectual, educational, and behavioural sequelae after cranial irradiation and chemotherapy.

Authors:  V Anderson; E Smibert; H Ekert; T Godber
Journal:  Arch Dis Child       Date:  1994-06       Impact factor: 3.791

9.  Voxel-based morphometry and diffusion-tensor MR imaging of the brain in long-term survivors of childhood leukemia.

Authors:  L Porto; C Preibisch; E Hattingen; M Bartels; T Lehrnbecher; R Dewitz; F Zanella; C Good; H Lanfermann; R DuMesnil; M Kieslich
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

Review 10.  Quantitative morphologic evaluation of magnetic resonance imaging during and after treatment of childhood leukemia.

Authors:  Wilburn E Reddick; Fred H Laningham; John O Glass; Ching-Hon Pui
Journal:  Neuroradiology       Date:  2007-07-26       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.